Speech-Language Pathologists in Texas City, TX Accepting Medicare
5 Speech-Language Pathologists found. Showing 1 - 5
 Christina Janay Smith Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1805 13th Ave N, Texas City, TX 77590 Phone: 409-916-0512 |
Rosalie Liuzza Blackledge, M.C.D. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1700 9th St N, Texas City, TX 77590 Phone: 281-627-8628 |
Rebecca Ann Giambra, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1700 9th Ave N, Texas City, TX 77590 Phone: 605-782-2300 |
Ms. Peggy D. Kelso, M.ED, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 424 Tarpey Rd, Texas City, TX 77591 Phone: 409-933-4700 Fax: 409-933-4700 |
Jennifer Ingrasin Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 210 Gulf Fwy, Texas City, TX 77591 Phone: 409-935-0300 |
News Archive
Targeting invasive cells could be a new strategy to treat metastatic cancer, say Stony Brook researchers
Most cancer drugs are designed to target dividing cells, but a new study by Stony Brook University researchers suggests that targeting invasive cells may be a new strategy to treat metastatic cancer.
Leading experts deliver breast cancer updates at unique public forum
While significant advances have been made in breast cancer care, evidence has shown that Ontarians diagnosed with breast cancer continue to face considerable challenges with their needs for information, support and care. To respond to these needs, the Canadian Breast Cancer Foundation - Ontario Region is working with leaders in research, clinical care and community support to deliver current breast cancer information and education at a free public forum presented by Scotiabank Group in Barrie called Breast Cancer Today: An Evening of Care and Community.
Preoperative chemotherapy reduces chemo-related infections
Giving chemotherapy to women with operable breast cancer before they have surgery 'not after' helps physicians pin down the best treatment regimen and can reduce the extent of surgery, according to a new systematic review.
iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015
iCo Therapeutics, today reported financial results for the quarter ended June 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").
› Verified 8 days ago
Chiropractors
Optometrists
Occupational Therapists
Podiatrists
Physical Therapists
Speech-Language Pathologists
Audiologists